Legend Biotech Corporation (LEGN)

Etorro trading 970x250
Legend Biotech Corporation (LEGN) Logo

About Legend Biotech Corporation

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel cell therapies for oncology and other indications. Its lead product candidate, LCAR-B38M/JNJ-4528, is an autologous CAR-T cell therapy that targets the B-cell maturation antigen. The company is conducting multiple clinical trials to evaluate LCAR-B38M/JNJ-4528 as an earlier line of therapy for multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in Revlimid-refractory MM. It also has a broad portfolio of earlier-stage autologous product candidates targeting various cancers, including non-hodgkins lymphoma (NHL), acute myeloid leukemia, and T cell lymphoma. In addition, the company is developing an allogeneic CAR-T product candidate targeting CD20 for the treatment of NHL, which is currently in an investigator-initiated Phase 1 clinical trial in China. Further, it has various product candidates in early preclinical and clinical development for the treatment of solid tumors, as well as infectious diseases. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation. Address: 2101 Cottontail Lane, Somerset, NJ, United States, 08873

Legend Biotech Corporation News and around…

Latest news about Legend Biotech Corporation (LEGN) common stock and company :

Legend Biotech to Highlight Continued Progress in the Treatment of Multiple Myeloma With Updated Data From BCMA CAR-T Studies at 2022 ASCO and EHA
18 May, 2022 FinancialContent

Legend Biotech announced that eight company-sponsored abstracts were accepted at ASCO and EHA 2022.

Legend Biotech Appoints Lori Macomber as Chief Financial Officer
09 May, 2022 FinancialContent

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the promotion of Lori Macomber, CPA, to Chief Financial Officer (CFO), effective immediately. Ms. Macomber assumes the role from Dr. Ying Huang, who has been both CFO and Chief Executive Officer (CEO) since September 2020. Dr. Huang will continue to serve as CEO of Legend Biotech.

Legend Biotech Announces Participation in Upcoming Investor Conferences
06 May, 2022 FinancialContent

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced its participation in the upcoming investor conferences:

HFCAA News: 128 Chinese Stocks the SEC Could Delist
05 May, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The SEC has released a massive list of Chinese stocks that could face delisting on Holding Foreign Companies Accountable Act news. The post HFCAA News: 128 Chinese Stocks the SEC Could Delist appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Investors ignore increasing losses at Legend Biotech (NASDAQ:LEGN) as stock jumps 7.3% this past week
03 May, 2022 Yahoo! Finance

Passive investing in index funds can generate returns that roughly match the overall market. But you can significantly...

Legend Biotech Achieves Milestone Under Collaboration Agreement with Janssen Biotech, Inc. for BCMA CAR-T
21 Apr, 2022 FinancialContent

Legend Biotech Achieves Milestone

2 Biotechs With Recent FDA Approvals to Hold for the Next Decade
06 Apr, 2022 FinancialContent

With trials aimed at increasing addressable markets in the coming years, Legend and Immunocore could reward investors.

Legend Biotech Announces Appointment of Global Head of Research and Early Development
01 Apr, 2022 FinancialContent

Legend Biotech Announces Appointment of Global Head of Research and Early Development, Guowei Fang, Ph.D.

Most Chinese Biotech Stocks Can Continue US Listing After New Audit Framework
01 Apr, 2022 FinancialContent

According to a Bloomberg report, U.S. regulators could reportedly have full access to auditing reports from most of the200-plus ...

EMA's CHMP Clears Janssen, Legend's Multiple Myeloma CAR-T Therapy
25 Mar, 2022 FinancialContent

The European Medicines Agency's CHMPrecommended conditional approvalof Janssen, a unit ofJohnson & ...

CARVYKTI® (ciltacabtagene autoleucel) Receives Positive CHMP Opinion for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
25 Mar, 2022 FinancialContent

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended Janssen Pharmaceutica NV’s marketing authorization of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.

UPDATE 2-European drug regulator clears J&J, Legend's CAR-T therapy
25 Mar, 2022 Yahoo! Finance

The European Medicines Agency on Friday recommended the use of Johnson & Johnson and its partner Legend Biotech Corp's CAR-T therapy to treat multiple myeloma, nearly a month after the treatment was cleared in the United States. The drug, Carvykti, was initially tested in China and later in the United States and Japan. Drugs that have only been tested in China have faced increased scrutiny by the U.S. Food and Drug Administration.

Flanders Investment and Trade Names Legend Biotech Newcomer of the Year
23 Mar, 2022 FinancialContent

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, was named Newcomer of the Year at the tenth annual Foreign Investment Trophy ceremony hosted by Flanders Investment & Trade (FIT).

Legend Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
18 Mar, 2022 FinancialContent

Legend Biotech announces fourth quarter and full-year 2021 results.

How The Pieces Add Up: FPX Headed For $138
16 Mar, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust US Equity Opportunities ETF (FPX), we found that the implied analyst target price for the ETF based upon its underlying holdings is $138.19 per unit.

Analyst Ratings For Legend Biotech
15 Mar, 2022 FinancialContent

Analysts have provided the following ratings for Legend Biotech (NASDAQ:LEGN) within the last quarter: Bullish Somewhat ...

Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2022
15 Mar, 2022 FinancialContent

Upgrades For Turquoise Hill Resources Ltd (NYSE:TRQ), BMO Capital upgraded the previous rating of Underperform to Market Perform. ...

12 Health Care Stocks Moving In Monday's Pre-Market Session
14 Mar, 2022 FinancialContent

Gainers Erytech Pharma (NASDAQ:ERYP) stock rose 18.7% to $1.65 during Monday's pre-market session. The market value ...

January 2023 Options Now Available For Legend Biotech (LEGN)
09 Mar, 2022 FinancialContent

Investors in Legend Biotech Corp (LEGN) saw new options begin trading today, for the January 2023 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 317 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

Legend Biotech Corporation's (NASDAQ:LEGN) Shift From Loss To Profit
09 Mar, 2022 Yahoo! Finance

Legend Biotech Corporation ( NASDAQ:LEGN ) is possibly approaching a major achievement in its business, so we would...

J&J in Partnership Talks with Two China Biopharmas
08 Mar, 2022 FinancialContent

Johnson & Johnson is currently talking with two China biopharmas about forming partnerships, though it did not name either company. J&J has a very good reason for being interested in China. Four years ago, its subsidiary, Janssen Pharma, formed a $1 billion partnership for Nanjing Legend Bio's CAR-T multiple myeloma therapy. At the time Legend wasn't particularly well known, but its CAR-T posted very high efficacy rates in a early trial. One week ago, Carvykti™ (cilta-cel) was approved for a US launch. More details.... Stock Symbol: (NYSE: JNJ) (NSDQ: LEGN) Share this with colleagues:

The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
06 Mar, 2022 FinancialContent

Biotech stocks reversed course in the week endingMarch 4, as the Ukrainian crisis weighed down on the broader market as well as ...

Week In Review: Adagene Forms $2.5 Billion, Four-Drug Partnership With Sanofi
05 Mar, 2022 FinancialContent

Adagene will apply its technology to as many as four Sanofi candidates in a collaboration worth up to $2.5 billion. Huadong Medicine will acquire Asia rights for two Heidelberg Pharma ADC candidates in a deal potentially worth more than $1 billion.

Up 1,000% in 5 Years? These Healthcare Stocks Could Pull It Off.
04 Mar, 2022 FinancialContent

Here's why our roundtable loves Legend Biotech, Heron Therapeutics, and Pieris Pharmaceuticals.

GenScript Losses Widen, But Investors Focus on Newly Approved Cancer Treatment
01 Mar, 2022 FinancialContent

Key takeaways: GenScript Biotech said it lost up to $519 million last year, with its Legend Biotech unit accounting for nearly 70% ...

Legend's stock is up 8%, the day after the FDA approves its CAR-T treatment
01 Mar, 2022 Yahoo! Finance

Shares of Legend Biotech Corp. were up 8.6% in premarket trading on Tuesday, the day after the company said that the Food and Drug Administration had approved the CAR-T therapy it developed with Johnson & Johnson as a multiple myeloma treatment. J&J's stock was down 0.8% in premarket trading on Tuesday. Legend had inked the licensing and collaboration deal with J back in 2017. The treatment is approved for adults with relapsed or refractory multiple myeloma who have already received four lines o

The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
01 Mar, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution ...

FDA Approves JNJ-Legend Biotech Partnered Blood Cancer Therapy
01 Mar, 2022 FinancialContent

TheFDA has approvedLegend Biotech Corporation's(NASDAQ: LEGN) first product, Carvykti (ciltacabtagene autoleucel; ...

Legend-Janssen CAR-T Therapy Approved in US for Multiple Myeloma
01 Mar, 2022 FinancialContent

Nanjing Legend and Janssen Pharma reported the US FDA approved their partnered CAR-T therapy as a fifth-line therapy for relapsed or refractory multiple myeloma. Carvykti™ (ciltacabtagene autoleucel) will compete against an already approved CAR-T, Abecma, which was developed by Bristol Myers Squibb and bluebird. According to Endpoints News, the Legend-Janssen CAR-T is priced at $465,000, slightly higher than the $419,500 for the BMS drug. Janssen-Legend contend that their drug has an advantage in long-term efficacy that will overcome their drug's higher price and second-to-market status. More details.... Stock Symbol: (NSDQ: LEGN) Share this with colleagues:

CARVYKTI™ (ciltacabtagene autoleucel), BCMA-Directed CAR-T Therapy, Receives U.S. FDA Approval for the Treatment of Adult Patients With Relapsed or Refractory Multiple Myeloma
01 Mar, 2022 FinancialContent

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved its first product, CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel), for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Legend Biotech entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc. (Janssen) to develop and commercialize cilta-cel in December 2017.

Legend Biotech Corporation (LEGN) is a NASDAQ Common Stock listed in , ,

970x250